Belgian consensus on the management of patients with functional dyspepsia.

K Van Malderen, F Wuestenberghs, C Van de Bruaene, H Vafa, M Surmont, K Routhiaux, S Nullens, T Mahler, P Latour, F de Clerck, H De Schepper, J Tack, T Vanuytsel, J Arts, S Kindt, H Piessevaux, P Caenepeel, J Schol, L Wauters, H Louis

Journal: Acta gastro-enterologica Belgica 2025;88(2):157-178

PMID: 40504583

Abstract

BACKGROUND

Functional dyspepsia (FD) is a disorder of gutbrain interaction characterised by epigastric pain, epigastric burning, early satiation or postprandial fullness. Despite its high prevalence, clinicians struggle with the diagnosis and management of these patients.

METHODS

A Delphi consensus was conducted by 20 experts from Belgium, and consisted of a literature review, summarising the existing evidence, and a voting process on 119 statements. Grading of recommendations, assessment, development and evaluation criteria were applied to evaluate the quality of evidence. Consensus was defined as > 80 % agreement.

RESULTS

Belgian consensus underlines the multifactorial aetiology of FD. In addition to the cardinal symptoms, bloating and weight loss are also observed in FD. Functional dyspepsia co-exists with other DGBIs, including IBS. Subtyping based on the postprandial nature of symptoms is recommended. Patients should receive a positive diagnosis. Additional testing is not routinely required before initiating therapy, except in the presence of alarm features or treatment-refractory symptoms, and can consist of upper GI endoscopy, abdominal imaging and gastric emptying testing. The consensus refuted the role of carbohydrate malabsorption testing, pyloric impedance planimetry, pH/impedance monitoring, food allergy testing and permeability testing in FD. Explanation and reassurance, also addressing lifestyle factors, represent the cornerstone of the management. Proton Pump Inhibitors are considered the firstline pharmacological treatment. With the exception of specific neuromodulators, the panel did not achieve consensus for other therapeutic options. This consensus recommends against restrictive diets, invasive endoscopic or surgical treatment, parenteral nutrition, antibiotics, spasmolytics and opioids in the management of FD.

CONCLUSION

A panel of Belgian experts summarised the existing evidence on the aetiology, presentation, diagnosis and treatment of FD with attention to the availability within the Belgian healthcare system. Areas of future research are identified.

© Acta Gastro-Enterologica Belgica.

Address: Vrije Universiteit Brussel (VUB), Brussels Health Campus/Faculty of Medicine and Pharmacy, Vitality Research Group, Laarbeeklaan 103, 1090 Brussels, Belgium.; Department of Gastro-enterology and Hepatology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels Health Campus, Medische Dienst, Laarbeeklaan 101, 1090 Brussels, Belgium.; Department of Gastroenterology, AZ Sint-Lucas, Brugge, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Gastroenterology, Ziekenhuis Oost-Limburg, Campus Sint-Jan, Genk, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; UHasselt, Hasselt, Belgium.; Department of Gastroenterology, AZ St-Lucas, Gent Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium.; Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium.; Department of Gastroenterology, Hepatology and Digestive Oncology, Centre Hospitalier Universitaire de Liè, Liège, Belgium.; Department of Pediatric Gastroenterology, Hôpital Universitaire de Bruxelles (H.U.B.), HUDERF, Brussels, Belgium.; ZAS Hospitals Antwerp, Antwerp, Belgium.; Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium.; Department of Hepato-gastroenterology, Cliniques universitaires St-Luc, Université catholique de Louvain, Brussels, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, Chirec Delta Hospital, Brussels, Belgium.; Sorbonne Paris Nord University, Department of Gastroenterology and Digestive Oncology, Avicenne Hospital, Paris Seine-Saint-Denis University Hospitals (HUPSSD); Greater Paris University Hospitals (AP-HP), Bobigny, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.